Melane Sampson, Author at BioTuesdays

Developments

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...

August 12, 2026

Developments

Clearmind announces positive results for intranasal MEAI

Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI...

August 11, 2026

Developments

SL Science co-authors Biomedicines article on γδ T Cell Therapy in Glioblastoma

SL Science Holding (NASDAQ: SLBT) has announced the publication of a peer-reviewed article in Biomedicines co-authored by SL Science leadership and clinical researchers from Taipei Medical University outlining a...

August 11, 2026

Developments

Vivos expands Greenway partnership

Vivos Therapeutics (NASDAQ: VVOS) has announced an expanded strategic engagement with closely held Greenway Health, a leading healthcare technology company, to deploy Greenway’s new AI-by-design Novare platform across...

August 11, 2026

Developments

Longeveron advances to final phase of XPRIZE Healthspan competition

Longeveron (NASDAQ: LGVN) announced that it has been selected from more than 600 worldwide applicants to advance to the final phase of the XPRISE Healthspan competition as a Milestone 2 Awardee team. The $1,000,000...

August 11, 2026

Developments

Silence reveals positive topline results from trial of divesiran in PV

Silence Therapeutics (NASDAQ: SLN) has announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). According...

August 10, 2026

Developments

USPTO grants Urteste patent for pancreatic cancer test

Urteste (WSE: URT) has announced that the United States Patent and Trademark Office (USPTO) granted a patent for Panuri, a non-invasive test for detecting pancreatic cancer. According to Urteste, the Panuri test is also...

August 6, 2026

Executive Moves

Defence appoints Dr. Amie Phinney as president and CEO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as president and CEO, effective August 1, 2026. Sébastien Plouffe, founder and CEO, will assume the position of executive...

August 6, 2026

Developments

First site in Indiana offers Aclarion’s Nociscan for lower back pain

Aclarion (NASDAQ: ACON, ACONW) has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology...

August 4, 2026

Developments

Elite launches generic Requip XL for Parkinson’s

Elite Pharmaceuticals (OTCQB: ELTP) has launched a generic version of Requip XL (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets, for the treatment of Parkinson’s...

August 4, 2026

Author - Melane Sampson

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Clearmind announces positive results for intranasal MEAI

SL Science co-authors Biomedicines article on γδ T Cell Therapy in Glioblastoma

Vivos expands Greenway partnership

Longeveron advances to final phase of XPRIZE Healthspan competition

Silence reveals positive topline results from trial of divesiran in PV

USPTO grants Urteste patent for pancreatic cancer test

Defence appoints Dr. Amie Phinney as president and CEO

First site in Indiana offers Aclarion’s Nociscan for lower back pain

Elite launches generic Requip XL for Parkinson’s

Subscribe